Principal Scientist | Project Manager | Neurodegeneration | Metabolic diseases | Obesity | Communication | Data Analysis
Antibody-drug conjugates (ADCs) represent a promising approach to cancer treatment, facilitating the targeted delivery of potent cytotoxic payloads directly to tumors. ADCs consist of a monoclonal antibody and a highly cytotoxic payload linked by a chemical linker. ADCs combine the target specificity and extended circulation half-life of antibodies with the potent anti-tumor properties of cytotoxic agents that may be too toxic for independent administration. This innovative molecular design holds significant potential in enhancing the efficacy and safety of cancer therapies. https://lnkd.in/eNf7S-S6